SCHEMBL475093

SCHEMBL475093

O=Cc1c(Cl)[nH]c(=O)[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TYMP P19971 19/20 0.61
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15331973 0.71 ACHE (0.53) TYMP
SCHEMBL15331802 0.71 TYMP (0.48) TYMPNPC1
SCHEMBL5154556 0.71 NPC1 (0.55) TYMPNPC1
SCHEMBL28448729 0.69 TYMP (0.56) TYMP
SCHEMBL17524430 0.65 TYMP (0.52) TYMP
SCHEMBL28441245 0.65 TYMP (0.45) TYMP
SCHEMBL10826303 0.65 TYMP (0.48) TYMP
SCHEMBL28433595 0.63 MEN1 (0.32)
SCHEMBL2884681 0.61 TYMP (0.53) TYMP
SCHEMBL16751121 0.61 KMT2A (0.42) TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4567260-A 6-CHLORO-5-FORMYL URACIL AND N-D-RIBITYL-=!O,4-XYLIDINE TOYO JOZO KABUSHIKI KAISHA (JP) 1986-01-28 US claimed
JP-59005186-A None JP disclosed
US-10457682-B2 Small molecules that bind MR1 THE UNIVERSITY OF CHICAGO 2019-10-29 US disclosed
EP-3274352-B1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Bayer Pharma AG (DE) 2019-01-02 EP disclosed
EP-3274352-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Bayer Pharma Aktiengesellschaft (DE) 2018-01-31 EP disclosed
WO-2016150901-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-29 WO disclosed
US-8575178-B2 Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-11-05 US disclosed
EP-2411397-B1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2013-05-29 EP disclosed
EP-2411397-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2012-02-01 EP disclosed
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-01-12 US disclosed
WO-2010109328-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 WO disclosed
US-4567260-A 6-CHLORO-5-FORMYL URACIL AND N-D-RIBITYL-=!O,4-XYLIDINE TOYO JOZO KABUSHIKI KAISHA (JP) 1986-01-28 US disclosed
US-4567260-A 6-CHLORO-5-FORMYL URACIL AND N-D-RIBITYL-=!O,4-XYLIDINE TOYO JOZO KABUSHIKI KAISHA (JP) 1986-01-28 US disclosed
JP-S595186-A NEW METHOD FOR 5-DEAZARIBOFLAVIN AND ITS INTERMEDIATE TOYO JOZO CO LTD 1984-01-12 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 TYMP 3034/4885NPC1 473/4885
US-10457682-B2 Small molecules that bind MR1 MICA, HLA-DRB1, CD74 TYMP 4808/4885NPC1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.